Acquisition - May 8, 2015
Gilead Buys EpiTherapeutics ApS
Gilead Sciences, Inc., has acquired EpiTherapeutics ApS for $65 million, subject to certain purchase price adjustments, to be financed through available cash on hand, according to FierceBiotech. EpiTherapeutics has a library of small molecule inhibitors of epigenetic regulation of gene transcription, in particular histone demethylases. The company’s lead pre-clinical compounds are being evaluated for the treatment of […]